三生制药拟向辉瑞配发 3114.25 万股 净筹约 7.85 亿港元
3SBIO announced that it has signed a licensing agreement with Pfizer, involving the PD-1/VEGF bispecific antibody (SSGJ-707). The agreement will take effect on July 24, 2025. Pfizer agrees to subscribe for 31.1425 million shares at a price of HKD 25.2055 per share, raising approximately HKD 785 million, with the subscription price representing a discount of about 17.09% to the market closing price
According to the Zhitong Finance APP, 3SBIO (01530) announced that it has entered into a licensing agreement with Pfizer regarding the PD-1/VEGF bispecific antibody (SSGJ-707).
All conditions precedent specified in the licensing agreement have been fulfilled, and therefore, the licensing agreement will take effect from July 24, 2025.
On July 24, 2025 (after trading hours), the company entered into a subscription agreement with Pfizer, under which Pfizer conditionally agreed to subscribe, and the company conditionally agreed to issue and allot 31,142,500 subscription shares at a subscription price of HKD 25.2055 per share, totaling approximately HKD 785 million. The subscription price per share represents a discount of approximately 17.09% to the closing price of HKD 30.40 per share reported on the Stock Exchange on the date of the subscription agreement
